Anlotinib ameliorates myositis-associated interstitial lung disease (MAILD) via suppression of the NETs-PI3K/Akt-driven epithelial-mesenchymal transition.
安罗替尼通过抑制NETs-PI3K/Akt驱动的上皮-间质转化来改善肌炎相关间质性肺病（MAILD）。
期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2025-006443
Yang Jumei, Chai Hui, Zhu Jiarui, Cui Xi, Li Wenjun, Su Qiyan, Guo Zhen, Feng Yingyue, Zhang Sigong
